Alberts, S.R., Sargent, D.J., Smyrk, T.C., Shields, A.F., Chan, E., Goldberg, R.M. et al. (2010) Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. Presented at the 46th Annual Meeting of the American Society of Clinical Oncology. 4-8 June, abstract CRA 3507.
2.
Bang, Y., Kwak, E.L., Shaw, A.T., Camidge, D.R., Iafrate, A.J., Maki, R.G. et al. (2010) Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK positive patients with non-small cell lung cancer (NSCLC) . Presented at the 46th Annual Meeting of the American Society of Clinical Oncology. 4-8 June, abstract 3.
3.
Burger, R.A., Brady, M.F., Bookman, M.A., Walker, J.L., Homesley, H.D., Fowler, J. et al. (2010) Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. Presented at the 46th Annual Meeting of the American Society of Clinical Oncology. 4-8 June, abstract LBA 1.
4.
Maione, P., Rossi, A., Sacco, P.C., Bareschino, M.A., Schettino, C., Ferrara, M.L. et al. (2010) Treating advanced non-small cell lung cancer in the elderly. Ther Adv Med Oncol2(4), in press.
5.
O’Day, S., Hodi, F.S., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B. et al. (2010) A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. Presented at the 46th Annual Meeting of the American Society of Clinical Oncology. 4-8 June, abstract 4.
6.
Quoix, E.A., Oster, J., Westeel, V., Pichon, E., Zalcman, G., Baudrin, L. et al. (2010) Weekly paclitaxel combined with monthly carboplatin versus single agent therapy in patients aged 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). Presented at the 46th Annual Meeting of the American Society of Clinical Oncology. 4-8 June, abstract 2.
7.
Twelves, C., Loesch, D., Blum, J.L., Vahdat, L.T., Petrakova, K., Chollet, P.J. et al. (2010) A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician’s choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. Presented at the 46th Annual Meeting of the American Society of Clinical Oncology. 4-8 June, abstract CRA 1004.
